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A B S T R A C T
There have been few cases in recent times where QT interval prolongation has been studied with regards
to the use of diphenhydramine. We present a case of a patient who presented because of shortness of
breath and needed emergent hemodialysis; during the course of which he developed prolonged QT
interval on electrocardiography, which was correlated interestingly with the use of diphenhydramine.
Pruritus is a common symptom experienced by dialysis patients. A less known, but rare side effect of
diphenhydramine is prolongation of QT interval. The histamine H1 receptor antagonist diphenhydra-
mine inhibits the fast sodium channels and at higher concentrations inhibits the repolarizing potassium
channels which leads to prolongation of the action potential and the QT interval. Diphenhydramine
toxicity is dose-dependent with a critical dose limit of 1.0 g.
Although a lot is known about the potential side effects of antihistamines, only a few cases have cited the
cardiac side effects. Thus, it is important for the clinician to be aware of this potentially serious
consequence of a commonly used drug, especially in the end-stage renal disease population. It is
important for clinicians to be aware of this rare yet dangerous side effect of diphenhydramine.
<Learning objective: Although a lot is known about the potential side effects of antihistamine drugs
little is described regarding cardiac side effects. Some antihistamines such as terfenadine have been
discontinued from the US market due to prolonged QT interval; therefore, it is important for the clinician
to be aware of potentially serious consequences of a commonly used drug such as diphenhydramine. We
describe a case of a patient who developed QT prolongation with a temporal association with
diphenhydramine usage.>
 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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Long QT interval due to prolonged repolarization may be
associated with polymorphic ventricular tachycardia known as
torsades de pointes (TdP). During marked prolongation of the
action potential (long QT), early after depolarizations may occur,
which, when propagated may trigger an arrhythmia. The duration
of QTc interval is the major determinant of the risk of drug-
induced TdP. Congenital long QT syndrome (LQTS), female gender,
hypokalemia, and use of sympathomimetics increase the risk of
TdP, and potentiate the QT prolonging effects of drugs. Antiar-
rhythmics that block the potassium channel prolong the QT and
increase the risk for TdP (amiodarone, sotalol, quinidine,* Corresponding author at: Advocate Christ Medical Center; 105 Covington Ct,
Oak Brook, IL 60523, USA. Tel.: +1 504 606 1773; fax: +1 504 457 0165.
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1878-5409/ 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rightprocainamide, ibutilide, disopyramide). Additionally, some
macrolide and ﬂuoroquinolone antibiotics, antipsychotic and
antidepressant drugs, serotonin agonists of the triptan class,
cisapride, dolasetron, and others have been reported to be
associated with QT prolongation or cases of TdP. Drug-induced
effects on the QT interval, with the associated possibility of
inducing fatal arrhythmias, have become a new challenge for the
practitioner, the drug development process, and the regulatory
agencies.
The association of diphenhydramine and QT prolongation is
extremely rare, and the association is only proposed and not
deﬁnite [1,2]. Our case demonstrates the proposed rare association
of diphenhydramine with prolongation of the QT interval.
Case report
The patient is a 55-year-old male, with a past medical history of
hypertension, end-stage renal disease related to hypertensives reserved.
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obesity, and pulmonary embolus on lifelong warfarin, presented
to the hospital with worsening shortness of breath and atypical
infraclavicular chest pain. He had a clogged arteriovenous ﬁstula,
not allowing the patient to receive dialysis treatments (or as
needed doses of diphenhydramine – which he received during
dialysis treatments) for a few days prior to admission. Electrocar-
diogram (ECG) on admission was unremarkable for any acute
abnormalities; of note, QTc was minimally prolonged (Fig. 1).
The initial diagnosis was ﬂuid overload due to not receiving
dialysis treatments over the previous few days but computerized
tomography (CT) with intravenous contrast was performed
because of subtherapeutic international normalized ratio. This
revealed bilateral multifocal acute pulmonary emboli. He was
placed on intravenous (IV) heparin drip for the treatment of
pulmonary embolus and scheduled for emergent hemodialysis and
ultimately had his arteriovenous ﬁstula revised by vascular
surgery. He was then transitioned to warfarin for his antic-
oagulation. During the course of his stay in the hospital, QT
prolongation was intermittently noted on telemetry monitoring,
temporally related to dialysis. Initially it was thought to be due to
electrolyte ﬂuxes during his hemodialysis, but ECG repeated up to
24 h later still showed persistent prolonged QTc. Later it became
apparent that he was given PRN doses of diphenhydramine 50 mg
on two consecutive days during dialysis which correlated with
prolonged QT intervals of 586 ms and 512 ms on ECGs taken
subsequently (Fig. 2). All liver function testing was unremarkable
throughout the hospitalization. Magnesium was found to be
elevated at 3.0 mg/dL on the ﬁrst day of hemodialysis but no
further levels were drawn. Calcium and phosphorous were normal
throughout the hospital course. The serum potassium was normal
during the hospital stay.
The half-life of diphenhydramine is 7–12 h; therefore, it is
conceivable that it was still present in the system after 24 h. Repeat
ECG that was taken after four half-lives of diphenhydramine
subsequently showed resolving QT interval with only mild
prolongation (Fig. 3).
Fortunately, the patient did not suffer from any arrhythmias
which can be a drastic consequence of a prolonged QT interval.
Another consideration is that the patient might have a forme fruste
of a QT prolonging mutation, which might make him more
susceptible to the QT prolonging effects of drugs. This patientFig. 1. Electrocardiogram on admission 11/27/2014 @ 10:58. No diphenhydramine denied genetic sequencing of the LQTS genes of the proband. Also,
no family members had previously been diagnosed with LQTS.
Discussion
Diphenhydramine and the older antihistamines are known for
their anticholinergic and sedative side effects. They also have been
proposed to cause arrhythmias. Terfanidine, an antihistamine drug,
was removed from the US market due to prolongation of the QT
interval less than 20 years ago. At that time, it was a commonly used
drug with over 100 million patients taking it. Most reports have
focused on the QT interval prolongation, due to an acute overdose of
diphenhydramine [3–7], rather than the more commonly used
lower doses. Takahara et al. have also documented the occurrence of
prolonged QT interval in halothane-anesthetized guinea pigs with
the overdose of cloperastine which is an antitussive agent with a
chemical structure similar to diphenhydramine [8]. In our case, the
patient used only the common low-dose PRN diphenhydramine but
interestingly enough, the abnormalities in the ECG correlated well
with the time of taking the diphenhydramine, and subsequently
subsided after the drug was avoided.
We speculate that our patient showed marked prolongation of
QTc after taking these small doses of diphenhydramine due to the
possibility of having a channelopathy causing QT prolongation.
Although no family members had been previously diagnosed with
LQTS, our patient may still carry a sporadic mutation or even have a
familial form of LQTS which could, sometimes, have low penetrance
in families.
All electrolytes were within normal limits despite being on
hemodialysis and the patient’s ECG changes were temporally
related to the diphenhydramine ingestion.
Diphenhydramine inhibits the potassium channels which can
cause QT interval prolongation and abnormal ventricular repolari-
zation, and these changes may be more marked if the patient
carries a mutant gene for LQTS. Most reported cases in the current
literature document the association of diphenhydramine with QT
prolongation at much larger doses, but our case is unique; in that
these changes occurred with small and usually administered doses.
It would be prudent for clinicians to be aware of this rare yet
potentially dangerous association of the commonly used over-the-
counter antihistamine, diphenhydramine.given. QT 380 ms/QTc 460 ms (mildly prolonged).
Fig. 2.
(a) Electrocardiogram on 11/29/2014 @ 12:23:28. Diphenhydramine 50 mg given on 11/28/2014 @ 18:46. QT 586 ms/QTc 555 ms (markedly prolonged). (b)
Electrocardiogram on 11/30/2014 @ 13:44. Diphenhydramine 50 mg given on 11/29/2014 @ 07:30. QT 512 ms/QTc 498 ms (markedly prolonged).
Fig. 3. Electrocardiogram on 12/1/2014 @ 05:40. No diphenhydramine given. QT 504 ms/QTc 472 ms (mildly prolonged).
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